| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
(R)-(+)-tert-Butylsulfinamide does not have a defined pharmacological target. It is a chiral reagent used in asymmetric synthesis. Its mechanism of action is chemical: the sulfinamide group acts as a chiral auxiliary, directing the stereoselective addition of nucleophiles to imines derived from it, enabling the synthesis of enantiomerically pure amines.
|
|---|---|
| ln Vitro |
In vitro, (R)-(+)-tert-butylsulfinamide is used as a chiral auxiliary in asymmetric synthesis. It is used to synthesize enantiomerically pure amines by reacting with aldehydes or ketones to form imines, which then undergo stereoselective addition of nucleophiles. The resulting sulfinamide products can be cleaved to release the chiral amine.
|
| ln Vivo |
In vivo activity data for (R)-(+)-tert-butylsulfinamide are not available, as the compound is a chiral reagent used for in vitro synthesis. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile.
|
| Enzyme Assay |
For in vitro chemical synthesis, (R)-(+)-tert-butylsulfinamide is used as a chiral auxiliary. Standard protocols involve reacting the sulfinamide with an aldehyde or ketone to form the corresponding imine. The imine is then reacted with a nucleophile (e.g., organometallic reagent) to form a new chiral center with high stereoselectivity. The sulfinamide auxiliary is then cleaved under acidic conditions to release the enantiomerically pure amine.
|
| Cell Assay |
For in vitro cell-based experiments, (R)-(+)-tert-butylsulfinamide is not typically used directly in cell culture. It is a chemical reagent used for asymmetric synthesis. The compound may be used in the synthesis of chiral compounds that are subsequently tested in cell-based assays.
|
| Animal Protocol |
In vivo animal studies for (R)-(+)-tert-butylsulfinamide are not applicable, as the compound is a chiral reagent used for synthesis. No animal studies have been conducted for this compound as a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (R)-(+)-tert-butylsulfinamide are not available, as the compound is not a drug and is not administered to living organisms. The compound is a solid and should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
(R)-(+)-tert-Butylsulfinamide is a research chemical and should be handled with appropriate laboratory safety precautions. As a sulfinamide, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
(R)-(+)-tert-Butylsulfinamide (CAS 196929-78-9) is primarily a research-grade chiral reagent, not an FDA-approved pharmaceutical drug. Its primary application is as a chiral auxiliary in asymmetric synthesis for the preparation of enantiomerically pure amines.
|
| Molecular Formula |
C4H11NOS
|
|---|---|
| Molecular Weight |
121.20
|
| Exact Mass |
121.056
|
| CAS # |
196929-78-9
|
| PubChem CID |
10964479
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
220.0±23.0 °C at 760 mmHg
|
| Melting Point |
103-107ºC
|
| Flash Point |
86.8±22.6 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
-0.62
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
7
|
| Complexity |
84.2
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(C)[S@@](=O)N
|
| InChi Key |
CESUXLKAADQNTB-SSDOTTSWSA-N
|
| InChi Code |
InChI=1S/C4H11NOS/c1-4(2,3)7(5)6/h5H2,1-3H3/t7-/m1/s1
|
| Chemical Name |
(R)-2-methylpropane-2-sulfinamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (825.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.2508 mL | 41.2541 mL | 82.5083 mL | |
| 5 mM | 1.6502 mL | 8.2508 mL | 16.5017 mL | |
| 10 mM | 0.8251 mL | 4.1254 mL | 8.2508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
